#ACR20 Dr. M. Crow on Lupus #StateofArtLecture reviews treatment of SLE: 1. HCQ is the foundation of Rx 2. keep pred <7.5mg/day 3. belimumab works better when given early in disease (<2 yrs) 4. combination Rx may be needed @rheumnow https://t.co/6zh1xkLXgN

So much more work to be done- the traditional tools for estimating CVD in rheumatic patients are likely not accurate especially patients with SLE- abstract 1286 @RheumNow #acr20 https://t.co/L6Z1fsO2he

Dr @AliDuarteMD presents on incidence of SLE over last 40 years, 29% increase overall, and doubled in males. Overall cyclical pattern. Abstr#1024 #ACR20 @rheumnow https://t.co/SSVY0U0SIg

Another addition to "Where you live matters!" NYC principal component analysis of 140 neighborhood characteristics show - location and SES influence incidence and severity of #COVID19 in #SLE @rheumnow #ACR20 ABS#0984

Toll-like Receptor Inhibitor Peptide Improves the Clinical, Immunologic, and Pathologic Manifestations of Systemic Lupus Erythematosus https://t.co/hAqngljp2b #sle #tollreceptorinhib TLR inhib in mice for SLE

• Toll-like Receptor Inhibitor Peptide Improves the Clinical, Immunologic, and Pa…

TMA and SLE by Dr Levy @SickKidsNews 👉TMA triad - microangiopathic hemolytic anemia, thrombocytopenia, impaired renal function 👉TTP pentad - fever, thrombocytopenia, hemolytic anemia, renal impairment, neurologic involvement #ACR20 #ACRambassador https://t.co/xnO1JkhSFT

Neighbourhood characteristics & socioeconomic factors important not only for contracting #COVID19 but also severe infection in #SLE. Results useful for developing strategies to address socioeconomic stressors in this population. Abs#0984 #ACR20 @RheumNow https://t.co/u4YDcfEcSQ

• Neighborhood Deprivation and Race/Ethnicity Affects COVID-19 Risk and Severity …

Time-trend analysis in hospitalised #infection in #lupus -Incr. rate of hospitalised infections over time -#Sepsis surpassed #pneumonia as most common hospitalised infection in 2011-12; twice as many sepsis vs pneumonia by 2015-16 Abs#0980 #ACR20 @RheumNow https://t.co/M8xbMDFUTS https://t.co/ShogvxbhzN

• Hospitalized Infections in Lupus: A Nationwide Study of Types of Infections, Ti…

Withdrawal of MMF may be safely in #SLE patients in remission #ACR20 @RheumNow Dr Chakravarty https://t.co/xnpagKNu96

Dr Joan Merrill presents a phase 2 trial use of Iberdomide in patients with #SLE -Novel MOA —> blocks TF Ailos and Ikaros Conclusion -Primary end point was met at week 24 -Effects greater in Aiolos high/Type 2 IFN high -Iverdomdie was tolerated well #Lupus #ACR20 #ACRambassador https://t.co/zpQR9ceV7p

Dr Richard Furie-> Obinutuzumab for proliferative #lupus nephritis -Compared to rituximab, has more B-cell depletion in tissue and #SLE patients -Meaningful benefits over SOC alone on renal response through week 104. -Phase 3 REGENCY pending. #ACR20 #ACRambassador #Rheumatology https://t.co/aPi1yueAiV

Can’t a clinician usually differentiate dermatomysitis skin changes from cutaneous lupus and if not would it affect your Rx of the skin involvement - HCQ, MMF, MTX, Aza & topicals. IL18 sigatures. But I get it. Impt for pathogenesis! @RheumNow #ACR2020 @CRASCRRheum https://t.co/RJh7fEVo4O

• https://twitter.com/rayzuomd/status/1325120875058896896

@andreafava representing @jhrheumatology @HopkinsBayview at plenary session! Urine proteomic biomarkers can revolutionize the way we see LN, and decrease need for renal Bx #Acr20 @RheumNow Abst#0936 https://t.co/zGoqmBPddT